News
NRXPW
0.1499
+2.39%
0.0035
Weekly Report: what happened at NRXPW last week (0415-0419)?
Weekly Report · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Ibotta, Blackstone, US health insurers
Wall Street's main stock indexes gained on Thursday. Dow Jones Industrial Average was up 0.11% at 37,793.34. Top three S&P 500 percentage gainers: Estee Lauder, United Airlines, Genuine Parts. Top two Nasdaq percentage losers: Las Vegas Sands and Tesla.
Reuters · 04/18 17:35
BUZZ-U.S. STOCKS ON THE MOVE-D.R. Horton, 23andMe, Copper miners
D.R. Horton, 23andMe, Copper miners rise as chip stocks rebound. Dow e-minis expected to open higher on Thursday. Investors await commentary from Federal Reserve officials on outlook for interest-rate cuts. 23andme rises after CEO considers taking firm private.
Reuters · 04/18 13:13
NRX PHARMACEUTICALS, INC. ANNOUNCES PRICING OF $2.0 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
Reuters · 04/18 12:30
BUZZ-U.S. STOCKS ON THE MOVE-U.S. chip stocks, Lithium Americas, Boeing Co
Futures for the S&P 500 and the Nasdaq gained on Thursday. Some chip stocks recouped losses after a sell-off. Investors await Federal Reserve policymakers' stance on interest-rate cuts. Lithium Americas, Boeing Co are among the day's losers.
Reuters · 04/18 11:15
NRX PHARMACEUTICALS, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
Reuters · 04/17 20:45
NRX PHARMACEUTICALS, INC. (NASDAQ:NRXP) ANNOUNCES NEW DATA ON NRX-101 DEMONSTRATING NO DAMAGE TO INTESTINAL AND VAGINAL FLORA IN VALIDATED RODENT MODELS COMPARED TO STANDARD ANTIBIOTICS: POTENTIAL IMPLICATIONS FOR AVOIDANCE OF C. DIFFICILE INFECTIONS
Reuters · 04/17 12:30
NRX PHARMACEUTICALS INC - HTX-100 IS EXPECTED TO BE MARKETED BY HOPE THERAPEUTICS, INC., A WHOLLY OWNED SUBSIDIARY OF NRX
Reuters · 04/15 12:30
Weekly Report: what happened at NRXPW last week (0408-0412)?
Weekly Report · 04/15 10:01
NRX PHARMACEUTICALS INC: POISED TO RECEIVE $320 MLN IN FURTHER MILESTONES ALONG WITH MID-TEEN ROYALTIES ON NET SALES
Reuters · 04/08 12:30
Weekly Report: what happened at NRXPW last week (0401-0405)?
Weekly Report · 04/08 10:03
NRX PHARMACEUTICALS INC: FORECASTS FIRST COMMERCIAL REVENUE IN 2024 FROM SALES OF KETAMINE AND RELATED TECHNOLOGIES
Reuters · 04/01 12:29
Weekly Report: what happened at NRXPW last week (0325-0329)?
Weekly Report · 04/01 10:02
Nrx Pharmaceuticals Inc: Current report
Press release · 03/28 22:42
Weekly Report: what happened at NRXPW last week (0318-0322)?
Weekly Report · 03/25 10:04
Weekly Report: what happened at NRXPW last week (0311-0315)?
Weekly Report · 03/18 10:03
Nrx Pharmaceuticals Inc: Other definitive proxy statementsOpen document
Press release · 03/11 22:22
Weekly Report: what happened at NRXPW last week (0304-0308)?
Weekly Report · 03/11 10:01
Weekly Report: what happened at NRXPW last week (0226-0301)?
Weekly Report · 03/04 10:03
BUZZ-U.S. STOCKS ON THE MOVE-Crypto stocks, Lowe's, Janux Therapeutics
U.S. Stock index futures rangebound as investors await inflation report and other economic data. Top three NYSE percentage gainers premarket: Surf Air Mobility, Janux Therapeutics, Lowe's. Crypto stocks jump as bitcoin exceeds $57K to 2-year high.
Reuters · 02/27 12:13
More
Webull provides a variety of real-time NRXPW stock news. You can receive the latest news about Nrx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXPW
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.